semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hypercholesterolaemia Participants diagnosed with Type 1 or Type 2 diabetes at least one year prior to the screening visit (Week -3) Signed written informed consent Participants with type 1 or type 2 diabetes treated with insulin whose LDL-C levels were not adequately controlled with maximally tolerated lipid-modifying therapy LDL-C of 70 mg/dL or greater years of age or more Glycosylated hemoglobin (HbA1c) less than 10% History of cardiovascular disease (including coronary heart disease [CHD] and/or CHD risk equivalents) and/or at least one additional cardiovascular risk factor  Not on a stable dose of statin or other lipid modifying therapy for at least 4 weeks prior to screening or from screening to randomization, unless statin intolerant Triglycerides >400 mg/dL Estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m² according to the Modification of Diet in Renal Disease (MDRD) equation Currently received or planned to receive renal replacement therapy (for example, hemodialysis) Change in weight of more than 5 kilograms within the prior 2 months Not on a stable dose/regimen of insulin or other antidiabetic drugs for the past 3 months or planned to intensify insulin regimen during the study Not treated with insulin for at least 6 months Planned to start new lipid modifying therapy or change dose of current lipid modifying therapy during the study Body mass index (BMI) >45 kg/m² or planned to undergo bariatric surgery, weight loss program, or initiate weight loss drugs during the study History of recent decompensation of diabetes within the prior 2 months (for example, diabetic ketoacidosis) The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Heart Failure History of heart failure with either reduced or preserved ejection fraction for 3 months Patients with New York Heart Association (NYHA) class II IV heart failure symptoms, with at least one worsening symptom (Dyspnea on exertion, shortness of breath, orthopnea, early satiety) and one sign of congestion (pulmonary rales, elevated jugular venous pressure10cmHg, peripheral edema and ascites) Decision by primary cardiologist or heart failure (HF) specialist to increase the home diuretic dose Stable treatment with beta-blockers for 1 month unless contraindicated (i.e. intolerance, bradycardia) as specified by primary cardiologist/HF provider Stable treatment with angiotensin converting enzyme-1 (ACE-1) or angiotensin receptor blocker (ARB) for 1 month Spironolactone dose 25mg or eplerenone 50mg per day Daily furosemide or furosemide equivalent dose of 80mg or greater Serum potassium concentration 4.5 mmol/L or 5.0 mmol/L if on potassium supplements Estimated Glomerular Filtration Rate (eGFR) by Modification of Diet in Renal Disease (MDRD) equation 40 ml/min/1.73  Inability to complete informed consent form Allergy or intolerance to spironolactone Systolic blood pressure <100 mmHg Patient in need of hospitalization per cardiologist decision Current inotrope dependency Current mechanical circulatory support Acute coronary syndromes or unstable angina within the past 4 weeks History of cardiac transplant Obstructive cardiac valvular disease Primary hypertrophic cardiomyopathy, infiltrative cardiomyopathy
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Hypertrophic Cardiomyopathy Patients with a typical or atypical hypertrophic cardiomyopathy (HCM) confirmed by imaging modalities (echo and MRI) and/or genetic tests or a relative history of HCM Left ventricular obstruction during exercise on treadmill (above 50 mmHg) Positive response to leg lifting test (obstruction reduction above 20 mmHg) at rest or in early recovery phase Daily symptoms as shortness of breath during exercise (NYHA2-3), non coronary chest pain, dizziness Correct ultrasound windows quality Sinus rhythm Optimal medical treatment For women, pregnancy test or contraception Written consent form obtained  Previous treatment by BX1514M Extra-cardiac pathology with life expectancy below than 1 year No capability of consent form written Pregnancy women Secondary hypertension hypertrophy, secondary valvular disease hypertrophy Permanent atrial fibrillation Severe ventricular arrhythmia without Implantable Cardioverter Defibrillator (ICD) Severe coronary disease Severe non stabilized hypertension Severe cardiopathy (ejection fraction below 40% or demonstrated elevated end diastolic pressure or pulmonary pressure above 60 mmHg)
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Hypercholesterolemia Males and Females 70 years old Received a statin as monotherapy while having a LDL-C >100 mg d/L at initial clinical washout visit OR Received no lipid-altering drugs since the initial clinic washout visit and had a mean LDL-C as follows at 2 qualifying visits ≥ 130 mg/dL if National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) Coronary Heard Disease (CHD) risk ≥ 10%; OR ≥ 160 mg/dL if NCEP ATP III CHD risk < 10% Had variability of 2 qualifying LDL-C <20% (i.e. lowest value/highest value >0.8). An additional qualifying visit may have been completed by patients who were washing off lipid medication in order to reassess LDL-C variability; and Had a mean LDL-C < 250 mg/dL at 2 qualifying visits  Women of childbearing potential, pregnant or lactating Body Mass Index (BMI) >38kg/m² TG >400 mg/dL at Visit B2 or B3 Unexplained creatinine phosphokinase (CPK) > 3 x Upper Limit of Normal (ULN) or those with a history of unexplained myopathy (including rhabdomyolysis) Documented cardiac history of: Myocardial infarction*, severe or unstable angina pectoris, coronary angioplasty, coronary artery bypass graft, symptomatic carotid artery disease or peripheral artery disease, ventricular arrhythmias, recurrent supraventricular tachycardia, abnormal QTC interval (QT corrected > 0.44 sec), heart failure or any other major cardiovascular event resulting in hospitalization Uncontrolled hypertension* Type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus (HbA1c >8%) or any diabetic patient who takes insulin and/or thiazolidinediones Renal dysfunction including chronic renal failure or insufficiency, or creatinine >2.0 mg/dL Hepatic dysfunction Uncontrolled hypothyroidism
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Advanced Cancers Diagnosis of cancer with evidence of active disease 2. Breakthrough dyspnea, defined as dyspnea with an average intensity level over the past 7 days of at least 3/10 on a numeric rating scale upon significant exertion or continuous dyspnea </=7/10 with worsening upon significant exertion 3. Outpatient at MD Anderson Cancer Center seen by the Supportive Care Service, Thoracic Medical Oncology, Cancer Pain Clinic, or Cardiopulmonary clinic 4. Ambulatory and able to walk with or without walking aid 5. On strong opioids with morphine equivalent daily dose of 80-500 mg for at least one week, with stable (i.e. +/ ) regular dose over the last 24 hours 6. Karnofsky performance status >/=50% 7. Age 18 or older 8. Able to complete study assessments  Dyspnea at rest >/=7/10 at the time of enrollment 2. Supplemental oxygen requirement >6 L per minute 3. Delirium (i.e. Memorial delirium rating scale >13) 4. History of unstable angina or myocardial infarction 1 month prior to study enrollment 5. Resting heart rate >120 at the time of study enrollment 6. Systolic pressure >180 mmHg or diastolic pressure >100 mmHg at the time of study enrollment 7. History of active opioid abuse within the past 12 months 8. History of allergy to fentanyl 9. Severe anemia (Hb <7g/L) if documented in the last month and not corrected prior to study enrollment* 10. Diagnosis of acute pulmonary embolism within past 2 weeks 11. Diagnosis of pulmonary hypertension 12. Unwilling to provide informed consent
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Achondroplasia Molecular or clinical diagnosis of achondroplasia (as confirmed by physical exam and/or radiograph review by the PI, one of the co-PIs or other qualified clinical geneticists) Subjects must have been seen for a clinical genetics visit at Johns Hopkins, Alfred I. DuPont Hospital for Children, University of Wisconsin-Madison or University of Texas Subjects may be active clinical patients at the above sites or no longer treated at a given site but with sufficient retrospective clinical data for extraction as determined by the PI or co-PIs  Skeletal dysplasia diagnosis other than heterozygous Achondroplasia There is no medical complication or condition which excludes a patient with achondroplasia
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 1.0-17.0,  Type 1 Diabetes Mellitus Ages: 1-17 years 2. diagnosis of type 1 diabetes within 4 months of enrollment 3. parent or guardian willing to sign informed consent to comply with basal bolus insulin treatment as well as study procedures and diet guidelines  Diabetes diagnosed under one year of age; 2. patients with known malabsorption or malnutrition; 3. glycosylated hemoglobin HbA1C value over 9% at three months following diagnosis (a general screen for noncompliance with treatment guidelines)
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 9.0-86.0,  Sarcoidosis Tuberculosis Subjects have ocular inflammation diagnosed as sarcoidosis, ankylosing spondylitis, behcet's disease Subjects have ocular infection diagnosed as tuberculosis and syphilis Subjects have refractive errors only  Subjects using ACE inhibitors, systemic steroids, immunosuppressive or immunomodulatory therapies
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chagas Disease to be a client of the TMS TeleHealth System, have a positive history for T cruzi infection or Chagas disease, have an abnormal ECG and to consent to participating in the research program  The pregnancy or breast feeding, and any severe condition with ominous prognosis that indicates a life expectancy of less than two years
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 19.0-75.0,  Hypertension Hypertrophy Written consent Age: 19 to 50 in Arm 1, 30 to 75 in Arm 2 Group 2A and 2E participants have left-ventricular hypertrophy Group 2B and 2F participants have diagnosed hypertrophic cardiomyopathy Group 2C and 2G participants are stable outpatients with NYHA class 1-3 heart failure with evidence of elevated LV mass (LVH), irrespective of LVEF Group 2D and 2H participants are stable patients with type 2 DM who have a HcA1c between 6.5-9% on oral hypoglycemic agents  Contraindications to MRI or MRI contrast agents Hemoglobin ≤ 9.0 gm/dL (only Group 2 participants) Glomerular filtration rate (based on MDRD Equation) < 30 ml/min/1.73m2 (only Group 2 participants) Any condition leading to a life expectancy <1 year Medically diagnosed claustrophobia Have received, or are scheduled to receive, another investigational medicinal product from 1 month prior to 1 month after in this study BMI of less than 18.5 or greater than 32 Group 1: medically diagnosed heart disease
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Diabetes, Type 1 Type 1 or insulin-dependent diabetic patients Patients treated with subcutaneous insulin pump with at least 2 episodes of severe hypoglycemia within 12 months before the study enrollment Affiliation to the french social security system or equivalent People who signed the consent form  Patient who have difficulty to understand the French language Patient can not be raised to the use of an insulin pump, or a glucose sensor Patient visually impaired Patient hard of hearing Pregnant woman or woman having a project of pregnancy within 6 months Persons referred to in Articles L1121-5 to L1121-8 CSP: pregnant woman, woman in labor, breastfeeding women, persons deprived of their liberty by judicial or administrative decision, person under a legal protection measure
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Informed consent will be obtained before any study-related activities. Study-related activities are any data collection from the medical records of the patient Age at least 18 years at the time of Tresiba® initiation T1DM or insulin-treated T2DM patients Switched to Tresiba® (with or without prandial insulin) after any basal insulin (with or without prandial insulin). Switch must have occurred at least 6 months prior to data collection and the patient may or may not be treated with Tresiba® at the time of patient selection Previously treated with any basal insulin (with or without prandial insulin) for at least 6 months prior to switching to Tresiba® At least one documented medical visit in the first 9 months after Tresiba® initiation Minimum available data at the time of Tresiba® initiation: age, type of diabetes, HbA1c (Glycated haemoglobin), duration of diabetes, duration and type of insulin treatment, medical follow-up at the study site of at least 1 year, and an eGFR (Estimated glomerular filtration rate )value in the last 12 months  Previous participation in this study. Participation is defined as having signed the Informed Consent Participation in a diabetes clinical trial or receipt of any investigational medicinal product up to 12 months before or any time after the initiation of Tresiba® Current participation in another non-interventional study on insulin degludec (Tresiba®) Patients treated by continuous subcutaneous insulin infusion or premix insulin in the 6 months prior to receiving Tresiba®
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 30.0-60.0,  Type 2 Diabetes Mellitus type 2 of diabetes diagnosed for 1 to 10 years age 30-60 years BMI = 18.5-35 kg/m*m treatment with Metformin or Glibenclamide  Treatment with insulin Weight loss more than 10% in 6 months Treatment with TZDs (thiazolidinediones) Pregnancy and breast feeding Smoking and alcohol consumption Multivitamin-mineral and polyphenols and omega-3 and 6 supplementation in the last 3 months and during study Ginger supplementation and herbal medicines Anticoagulation consumption such as heparin and warfarin NSAIDs such as diclofenac and salicylate drugs such as aspirin, corticosteroids such as prednisone consumption during 1 month ago and during the study Infectious and inflammatory diseases such as rheumatoid arthritis